Onco Actu du 30 septembre 2015

	3.1 Tabac
Expert Opinion – Dr Mark Hellowell & Dr Katherine Smith on ‘earmarked’ funding for tobacco control [Cancer Research UK] We asked Dr Mark Hellowell, an expert in health financing, and Dr Katherine Smith, who has examined tobacco industry responses to different forms of taxation, both from the University of Edinburgh, to explain the economics of how a tobacco levy would work, and the concept of ’hypothecation’.
Prison smoking ban to begin in 2016 [BBC News] Smoking will be banned in all prisons in Wales and four in south-west England from next year, the government says.
U.S. states urge FDA to ensure warnings on liquid nicotine products [Reuters] The attorneys general in a letter on Tuesday urged the health regulator to take immediate action to stem the increasing incidence of liquid nicotine poisoning among children.
	5. Traitements
Inroads against leukemia [Harvard Gazette] Potential for halting disease in molecule isolated from sea sponges.
	5.2 Pharma
Don't be quick to peg Merck's Keytruda in second place for NSCLC, analyst says [FiercePharma] Roche could quickly come in and complicate matters; its atezolizumab is coming on strong with a "breakthrough" designation in lung cancer and potential approval next year.
	5.2.3 Pharma - économie
It’s time for the drug industry to talk about prices [The Boston Globe] Like safety warnings in a pharmaceutical ad, the industry may hope we look the other way, but Shkreli is a side effect that is simply too hard to ignore.
	5.6.11 ESMO- Rein
ESMO Commentary: New promising options are available for kidney cancer [ESMO] Two drugs are changing the current landscape for the treatment of advanced metastatic renal cell carcinoma, prolonging survival.
	5.6.13 ESMO - Prostate
First data from Europe’s first and largest prospective observational study of metastatic castration-resistant prostate cancer (mCRPC) presented at the 2015 European Cancer Congress (ECC2015) [Janssen] With the aim of enrolling a total of 3,000 patients, to date more than 2,500 mCRPC patients from 192 centres in 16 European countries have so far been enrolled.
	5.6.2 ESMO - Divers
ESMO Commentary: TOPGEAR results set to unify global treatment of gastric cancer [ESMO] “The TOPGEAR trial compares a control arm, with the MAGIC approach (epirubicin, cisplatin and 5-FU), with the experimental arm, which includes 2 cycles of the same chemotherapy regimen followed by chemo radiotherapy with 5-FU. After surgery, both groups receive the same chemotherapy treatment used in the MAGIC trial.”
ESMO Commentary: Specialised staff required for the nutrition and family teams in supportive care [ESMO] Ideally, supportive programmes should be provided from the time of diagnosis, be adaptive and flexible to the needs of cancer patients and their families during their illness trajectory, and be integrated into the existing healthcare system at all levels of care, including community and home-based. However, the real situation in Europe is different from the ideal one.
	6.7 DMP, Big Data & applis
The Social Network Where Doctors Swap Gross Pics of Patients [WIRED] As Figure 1 grows, it has the potential to become global health’s central nervous system—improving diagnostics, care, and treatment for non-users everywhere.
Real Precision Medicine Requires Real Access To Patient Data [Forbes] The lack of easily-accessible health data is a major current unmet need in the United States. I learned this firsthand in 1996 when, at the age of 37, I was unexpectedly diagnosed with multiple myeloma, a rare and fatal blood cancer.
Information Blocking by E-Health Record Firms Threatens CancerLinQ, ASCO Says [The Cancer Letter] ASCO is at the heart of this Big Data controversy because it is developing the CancerLinQ database. If oncology practices are precluded from sharing data—as they increasingly are—CancerLinQ will become unworkable.
U.S. biotech to apply artificial intelligence to UK genome study [Reuters] The project focuses on patients with rare diseases and six common cancers. Industry partners include drugmakers such as Roche, Biogen, AstraZeneca and GlaxoSmithKline.
	6.8 Communication
Media coverage of Angelina Jolie’s mastectomy boosts awareness of reconstructive breast surgery [Cancer Research UK] “As this fascinating study shows, when celebrities talk publicly about their experiences of cancer it can have a big impact on ordinary people’s attitudes, awareness and behaviour.”
Angelina Jolie boosts awareness on breast cancer, reconstruction surgery [The Globe & Mail] “The key finding was that Mrs. Jolie’s announcement did indeed affect the public opinion going beyond gene-positivity [and] actually improving the awareness that breast reconstruction can be achieved with the use of one’s own tissue and that it can be done during the breast-removal operation.”